Specific Targeting of Monomeric SOD1 as a Potential Immunotherapeutic Strategy for ALS.

单体 SOD1 的特异性靶向作为 ALS 的潜在免疫治疗策略。

• 批准号: 225007
• 负责人: Marciniuk Kristen
• 金额: $ 1.27万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-02-01 至 2012-02-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=225007&lang=en
• 关键词: Als; Disease Specific Epitopes; Immunotherapy; Protein Misfolding; Recombinant Fusions; Sod1

Amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of motor neurons leading to spasticity, over responsive reflexes, generalized weakness, musc

肌萎缩侧索硬化症（ALS），通常被称为卢伽雷氏病，是一种进行性神经退行性疾病，其特征是运动神经元的选择性丧失，导致痉挛、反应过度反射、全身无力、肌肉无力。